Nifty
Sensex
:
:
14238.90
48347.59
-133.00 (-0.93%)
-530.95 (-1.09%)

Pharmaceuticals & Drugs - Global

Rating :
50/99

BSE: 506690 | NSE: UNICHEMLAB

293.85
25-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  294.45
  •  296.45
  •  289.10
  •  292.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  85198
  •  249.36
  •  304.70
  •  80.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,069.23
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,019.45
  • 1.36%
  • 0.78

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.93%
  • 2.80%
  • 30.76%
  • FII
  • DII
  • Others
  • 1.55%
  • 8.59%
  • 5.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.92
  • -1.90
  • -4.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.35
  • 23.58
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.54
  • 0.54
  • 0.54

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.95
  • 26.88
  • 34.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
317.51
268.14
18.41%
317.27
273.20
16.13%
320.23
374.90
-14.58%
0.00
0.00
0
Expenses
287.65
294.94
-2.47%
305.19
293.42
4.01%
306.87
349.56
-12.21%
0.00
0.00
0
EBITDA
29.86
-26.81
-
12.08
-20.22
-
13.36
25.34
-47.28%
0.00
0.00
0
EBIDTM
9.40%
-10.00%
3.81%
-7.40%
4.17%
6.76%
0.00%
0.00%
Other Income
10.04
28.13
-64.31%
16.71
26.26
-36.37%
11.82
20.71
-42.93%
0.00
0.00
0
Interest
0.79
1.86
-57.53%
1.25
1.28
-2.34%
2.40
4.22
-43.13%
0.00
0.00
0
Depreciation
21.13
20.98
0.71%
20.54
18.25
12.55%
22.96
19.03
20.65%
0.00
0.00
0
PBT
17.98
-21.51
-
7.00
-13.49
-
-0.17
22.81
-
0.00
0.00
0
Tax
9.25
0.68
1,260.29%
4.61
-7.53
-
17.63
-9.01
-
0.00
0.00
0
PAT
8.74
-22.19
-
2.39
-5.96
-
-17.80
31.82
-
0.00
0.00
0
PATM
2.75%
-8.27%
0.75%
-2.18%
-5.56%
8.49%
0.00%
0.00%
EPS
1.24
-3.15
-
0.35
-0.88
-
-2.44
5.40
-
0.00
0.00
0

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
-
1,210.62
1,188.19
1,379.90
1,540.06
1,332.65
1,201.79
1,133.45
1,080.80
875.46
824.04
Net Sales Growth
-
1.89%
-13.89%
-10.40%
15.56%
10.89%
6.03%
4.87%
23.46%
6.24%
 
Cost Of Goods Sold
-
308.19
364.19
274.97
188.77
386.97
378.57
332.84
343.06
278.55
237.98
Gross Profit
-
902.43
823.99
1,104.93
1,351.28
945.67
823.23
800.61
737.75
596.91
586.07
GP Margin
-
74.54%
69.35%
80.07%
87.74%
70.96%
68.50%
70.63%
68.26%
68.18%
71.12%
Total Expenditure
-
1,261.44
1,269.21
1,358.21
1,357.62
1,168.77
1,100.79
955.75
910.06
759.42
674.08
Power & Fuel Cost
-
73.02
76.39
49.23
41.62
38.25
39.39
35.97
31.36
26.22
22.50
% Of Sales
-
6.03%
6.43%
3.57%
2.70%
2.87%
3.28%
3.17%
2.90%
2.99%
2.73%
Employee Cost
-
273.28
238.52
200.64
169.04
255.92
223.20
187.37
164.88
140.06
123.99
% Of Sales
-
22.57%
20.07%
14.54%
10.98%
19.20%
18.57%
16.53%
15.26%
16.00%
15.05%
Manufacturing Exp.
-
151.01
147.23
125.30
103.70
150.54
145.03
137.05
119.15
101.54
102.67
% Of Sales
-
12.47%
12.39%
9.08%
6.73%
11.30%
12.07%
12.09%
11.02%
11.60%
12.46%
General & Admin Exp.
-
228.99
229.37
594.53
744.66
167.66
153.29
127.77
104.73
88.54
79.74
% Of Sales
-
18.92%
19.30%
43.09%
48.35%
12.58%
12.76%
11.27%
9.69%
10.11%
9.68%
Selling & Distn. Exp.
-
223.02
197.24
108.38
107.77
166.84
157.12
134.03
135.93
116.00
106.52
% Of Sales
-
18.42%
16.60%
7.85%
7.00%
12.52%
13.07%
11.82%
12.58%
13.25%
12.93%
Miscellaneous Exp.
-
3.93
16.26
5.16
2.06
2.58
4.19
0.73
10.97
8.50
106.52
% Of Sales
-
0.32%
1.37%
0.37%
0.13%
0.19%
0.35%
0.06%
1.01%
0.97%
0.08%
EBITDA
-
-50.82
-81.02
21.69
182.44
163.88
101.00
177.70
170.74
116.04
149.96
EBITDA Margin
-
-4.20%
-6.82%
1.57%
11.85%
12.30%
8.40%
15.68%
15.80%
13.25%
18.20%
Other Income
-
91.31
98.41
3,278.19
5.50
19.11
20.72
42.38
16.96
12.50
8.32
Interest
-
7.85
7.52
8.01
3.36
2.90
3.04
3.19
3.29
4.08
2.39
Depreciation
-
81.67
67.37
50.51
43.52
38.79
41.27
45.72
38.34
30.43
29.22
PBT
-
-49.02
-57.50
3,241.36
141.07
141.31
77.41
171.17
146.07
94.03
126.66
Tax
-
11.97
-33.64
696.23
32.58
29.30
2.13
43.00
32.85
22.77
31.68
Tax Rate
-
-24.42%
58.50%
21.48%
23.09%
21.27%
2.75%
25.12%
22.49%
24.22%
25.01%
PAT
-
-61.00
-23.87
2,545.13
108.49
108.48
75.28
128.16
113.23
71.26
94.98
PAT before Minority Interest
-
-61.00
-23.87
2,545.13
108.49
108.48
75.28
128.16
113.23
71.26
94.98
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
-5.04%
-2.01%
184.44%
7.04%
8.14%
6.26%
11.31%
10.48%
8.14%
11.53%
PAT Growth
-
-
-
2,245.96%
0.01%
44.10%
-41.26%
13.19%
58.90%
-24.97%
 
EPS
-
-8.66
-3.39
361.52
15.41
15.41
10.69
18.20
16.08
10.12
13.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
2,531.35
2,619.91
2,680.08
1,063.62
954.33
867.52
816.61
727.07
660.58
617.70
Share Capital
14.08
14.08
14.07
18.18
18.17
18.15
18.13
18.09
18.06
18.05
Total Reserves
2,512.44
2,601.99
2,665.42
1,044.00
935.01
848.52
797.74
707.98
641.80
598.85
Non-Current Liabilities
43.72
10.10
46.46
64.49
76.02
74.21
97.72
94.31
92.67
87.44
Secured Loans
0.00
0.00
0.33
0.44
22.98
20.35
24.65
20.89
20.47
19.01
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
23.49
22.72
Long Term Provisions
23.51
14.60
10.76
25.33
12.58
8.88
7.64
9.19
10.24
7.90
Current Liabilities
566.73
502.92
463.51
392.62
275.09
211.76
230.32
251.12
233.30
176.15
Trade Payables
250.22
221.41
226.23
210.73
163.95
138.23
150.52
156.63
140.30
109.99
Other Current Liabilities
122.04
68.45
63.03
68.01
60.56
45.86
32.99
36.65
34.28
26.00
Short Term Borrowings
184.03
199.67
150.29
97.62
12.93
1.63
1.04
6.17
25.42
9.04
Short Term Provisions
10.44
13.39
23.97
16.25
37.65
26.05
45.78
51.67
33.30
31.13
Total Liabilities
3,141.80
3,132.93
3,190.05
1,520.73
1,305.44
1,153.49
1,144.65
1,072.50
986.55
881.29
Net Block
866.06
806.29
574.45
487.22
402.60
415.99
419.29
447.76
408.39
377.31
Gross Block
1,103.64
975.96
689.74
561.37
439.53
724.65
688.25
675.87
599.27
537.04
Accumulated Depreciation
237.59
169.67
115.29
74.15
36.92
308.66
268.96
228.11
190.87
159.73
Non Current Assets
1,455.33
1,093.64
853.59
772.27
673.34
589.07
563.97
594.06
547.20
456.50
Capital Work in Progress
330.47
92.39
238.15
249.98
237.13
122.64
90.54
132.20
112.76
62.87
Non Current Investment
134.38
129.20
9.20
9.51
5.54
5.83
5.72
5.72
0.03
0.03
Long Term Loans & Adv.
112.90
56.37
24.05
25.57
28.05
44.61
48.42
8.38
26.02
16.29
Other Non Current Assets
11.52
9.39
7.74
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,686.47
2,039.29
2,336.47
748.46
632.11
564.42
580.68
478.44
439.35
424.79
Current Investments
419.10
800.75
895.55
8.00
8.04
35.04
5.67
33.06
14.50
21.29
Inventories
396.54
338.66
272.86
281.71
230.57
207.68
203.49
143.05
157.96
150.26
Sundry Debtors
390.14
436.05
276.92
315.32
220.09
191.58
196.51
206.95
183.25
185.13
Cash & Bank
233.81
200.99
681.46
16.14
20.13
26.96
52.15
24.64
23.23
15.16
Other Current Assets
246.88
68.65
64.17
28.49
153.28
103.17
122.86
70.75
60.40
52.95
Short Term Loans & Adv.
183.04
194.18
145.51
98.80
122.77
82.25
105.67
61.73
53.14
47.14
Net Current Assets
1,119.74
1,536.37
1,872.95
355.84
357.02
352.66
350.36
227.32
206.05
248.65
Total Assets
3,141.80
3,132.93
3,190.06
1,520.73
1,305.45
1,153.49
1,144.65
1,072.50
986.55
881.29

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
19.82
-327.77
-112.34
68.19
111.91
78.10
86.73
171.23
124.08
68.59
PBT
-48.21
-57.44
3,241.14
141.25
137.68
77.41
171.17
146.07
94.03
126.66
Adjustment
18.79
6.80
-3,207.66
53.31
39.65
35.57
18.74
47.15
39.37
27.54
Changes in Working Capital
53.58
-264.94
-146.67
-98.65
-34.16
-16.49
-66.32
13.05
13.51
-54.81
Cash after chg. in Working capital
24.15
-315.57
-113.20
95.91
143.16
96.49
123.58
206.27
146.91
99.39
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-4.34
-12.20
0.86
-27.72
-31.25
-18.39
-36.85
-35.04
-22.83
-30.81
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-41.21
-286.01
1,648.33
-127.87
-85.33
-52.34
35.70
-118.45
-101.80
-47.60
Net Fixed Assets
-338.73
-139.02
-107.71
-135.60
154.89
-73.58
38.14
-92.98
-106.47
-67.03
Net Investments
374.24
-63.59
-889.36
17.40
42.09
-32.73
20.34
-34.14
-5.98
28.17
Others
-76.72
-83.40
2,645.40
-9.67
-282.31
53.97
-22.78
8.67
10.65
-8.74
Cash from Financing Activity
-62.30
-2.42
-881.13
59.23
-33.42
-50.95
-94.92
-51.38
-14.21
-29.46
Net Cash Inflow / Outflow
-83.69
-616.19
654.86
-0.46
-6.84
-25.19
27.51
1.41
8.07
-8.48
Opening Cash & Equivalents
197.05
666.07
11.21
11.67
26.96
52.15
24.64
23.23
15.16
23.64
Closing Cash & Equivalent
226.22
197.05
666.07
11.21
20.13
26.96
52.15
24.64
23.23
15.16

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
358.85
371.69
380.95
116.88
104.93
95.48
90.02
80.27
73.06
68.36
ROA
-1.94%
-0.75%
108.06%
7.68%
8.82%
6.55%
11.56%
11.00%
7.63%
11.31%
ROE
-2.37%
-0.90%
136.04%
10.77%
11.92%
8.95%
16.62%
16.34%
11.16%
16.11%
ROCE
-1.49%
-1.77%
162.77%
13.42%
14.97%
9.29%
21.84%
20.13%
14.03%
20.37%
Fixed Asset Turnover
1.16
1.43
2.21
3.08
2.32
1.71
1.67
1.71
1.55
1.66
Receivable days
124.55
109.51
78.30
63.41
55.72
58.55
64.53
65.42
76.34
77.46
Inventory Days
110.83
93.93
73.33
60.67
59.32
62.03
55.42
50.47
63.88
56.72
Payable days
74.71
73.41
94.97
104.25
52.00
52.61
62.52
65.77
65.64
63.82
Cash Conversion Cycle
160.67
130.03
56.65
19.82
63.05
67.97
57.43
50.11
74.58
70.36
Total Debt/Equity
0.07
0.08
0.06
0.09
0.04
0.03
0.03
0.04
0.11
0.08
Interest Cover
-5.25
-6.64
405.79
43.00
48.57
26.45
54.66
45.40
24.06
53.94

News Update:


  • Unichem Laboratories gets ANDA approval for Celecoxib Capsules
    13th Jan 2021, 12:54 PM

    The product will be commercialized from Unichem’s Goa Plant

    Read More
  • ICRA reaffirms Unichem Laboratories’ long-term rating
    8th Jan 2021, 15:58 PM

    The outlook on the long term rating has been revised to stable from negative

    Read More
  • Unichem Laboratories gets ANDA's approval for Atenolol, Chlorthalidone Tablets
    30th Nov 2020, 08:14 AM

    The product will be commercialized from the company’s Ghaziabad Plant

    Read More
  • Unichem Laboratories turns black in Q2
    2nd Nov 2020, 12:17 PM

    Total consolidated income of the company increased by 10.56% at Rs 327.55 crore for Q2FY21

    Read More
  • Unichem Lab - Quarterly Results
    31st Oct 2020, 14:25 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.